Role of Advanced Magnetic Resonance Imaging Techniques in the Evaluation of Intracranial Masses and Mass like Lesions

Authors
Deba Kumar Chakrabarty¹, Bhaskar Jyoti Pegu², Atul Kumar Singh³

¹Head of the department
²Assistant professor
*Corresponding Author
Atul Kumar Singh

Introduction
Intracranial mass lesions are a broad and very disparate group of pathological conditions ranging from brain tumours to non-neoplastic conditions such as abscess or neurocysticercoses. Intracranial mass lesions are a significant health problem and present several imaging challenges and radiology has played an integral role in the diagnosis, monitoring, and treatment planning of intracranial masses. MRI in particular, offers superior soft-tissue contrast over other cross-sectional imaging techniques allowing for better visualisation of subtly infiltrated or disrupted parenchymal architecture, has emerged as the imaging modality of choice. However, in many cases, conventional MRI which provides useful structural findings are not enough for an accurate diagnosis.
Neuro-oncological imaging has evolved from a purely anatomy-based discipline to one that incorporates morphologic abnormality with physiologic alterations, cellular metabolism, and hemodynamics. Tremendous progress and widespread clinical use of physiology-based MR imaging have become an essential part of the diagnostic armamentarium to diagnose, guide surgery, monitor therapy response, and predict prognosis of patients with a brain tumour. The current most commonly used advanced techniques include diffusion-weighted imaging (DWI), MR Spectroscopy (MRS), Perfusion-weighted imaging (PWI) and Susceptibility weight imaging (SWI). These methods have played a pivotal role in the transition of clinical MR imaging from a purely morphology-based discipline to one that combines structure with function.
Integration of diagnostic information from above mentioned advanced MR imaging techniques can evaluate different tumour types, predict tumour grade, improve the classification accuracy, further differentiate tumour from non-neoplastic lesions, serially and noninvasively monitor tumour progression, and monitor the efficacy of therapy.

Materials and Methods
The present study was conducted in the Department of Radiology, Silchar Medical College and Hospital, Silchar for a period of one year from 1st of June 2019 to 31st of May 2020. Patients referred for radiological evaluation with clinically suspected intracranial mass of Silchar
Medical College and Hospital of all age groups and genders were included. Patients with traumatic brain injury or had general contraindication for MRI and gadolinium-based contrast media were excluded. All of the patients underwent MR imaging study on a SIEMENS AVANTO FIT 1.5T SCANNER using a standard head coil with 240 x 240-mm FOV. Localizing sagittal T1W were obtained, then axial and sagittal T1W, axial and coronal T2-weighted, and axial FLAIR images of the brain were obtained. SWI and DW MR imaging was acquired in the axial plane. For PWI, a series of T2*-weighted gradient-EPI was then acquired during the first pass of a bolus of contrast agent. Finally, contrast-enhanced axial T1-WI were obtained. MRS obtained with Multivoxel technique at intermediate TE=135 ms.

In all cases, conventional and advanced MRI sequences were taken. Final diagnosis was done after correlation of imaging findings with clinical diagnosis, histopathological diagnosis, biochemical analysis and follow up scans when the patient was on conservative treatment.

**Results**

Our study included 60 patients of both sexes and 44 (73.33%) patients had neoplastic lesions and 16 (26.67%) patients had non-neoplastic mass like lesions. Most common pathologies were metastases (25.00%), high grade glioma (16.67%), meningioma (15.00%), low grade glioma (8.33%), DNET (6.67%), abscesses (10%), tuberculoma (8.33%), neurocysticercoses (8.33%), and medulloblastoma (1.67%).

**Table 1:** Distribution of cases according to the final diagnosis and distribution of lesions in different age groups and gender

<table>
<thead>
<tr>
<th>Pathology</th>
<th>No. of Cases</th>
<th>Percentage</th>
<th>Age (Mean±SD)</th>
<th>M:F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoplastic</td>
<td>44</td>
<td>73.33%</td>
<td>50.27±15.82</td>
<td>5:4</td>
</tr>
<tr>
<td>High Grade Glioma</td>
<td>10</td>
<td>16.67%</td>
<td>54.90±16.35</td>
<td>3:2</td>
</tr>
<tr>
<td>Glioblastoma Multiforme</td>
<td>6</td>
<td>10%</td>
<td>62.50±5.89</td>
<td>1:1</td>
</tr>
<tr>
<td>Grade III Astrocytoma</td>
<td>3</td>
<td>5%</td>
<td>54.00±4.58</td>
<td>2:1</td>
</tr>
<tr>
<td>Diffuse Midline Glioma</td>
<td>1</td>
<td>1.67%</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Low Grade Glioma</td>
<td>5</td>
<td>8.33%</td>
<td>43.00±2.94</td>
<td>3:2</td>
</tr>
<tr>
<td>Grade II Astrocytoma</td>
<td>4</td>
<td>6.67%</td>
<td>43.00±2.94</td>
<td>3:1</td>
</tr>
<tr>
<td>Grade II Oligodendroglioma</td>
<td>1</td>
<td>1.67%</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Meningioma</td>
<td>9</td>
<td>15.00%</td>
<td>51.33±8.31</td>
<td>1:2</td>
</tr>
<tr>
<td>Atypical Meningioma</td>
<td>2</td>
<td>3.33%</td>
<td>48.50±9.19</td>
<td>1:1</td>
</tr>
<tr>
<td>Benign Meningioma</td>
<td>7</td>
<td>11.67%</td>
<td>52.14±8.63</td>
<td>5:2</td>
</tr>
<tr>
<td>DNET</td>
<td>4</td>
<td>6.67%</td>
<td>20.00±2.58</td>
<td>3:1</td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>1</td>
<td>1.67%</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td>15</td>
<td>25%</td>
<td>59.94±8.46</td>
<td>3:2</td>
</tr>
<tr>
<td>Non-Neoplastic</td>
<td>16</td>
<td>26.67%</td>
<td>42.25±12.86</td>
<td>1.3:1</td>
</tr>
<tr>
<td>Abscess</td>
<td>6</td>
<td>10%</td>
<td>48.00±5.62</td>
<td>2:1</td>
</tr>
<tr>
<td>Tuberculoma</td>
<td>5</td>
<td>8.33%</td>
<td>35.20±16.04</td>
<td>3:2</td>
</tr>
<tr>
<td>Neurocysticercosis</td>
<td>5</td>
<td>8.33%</td>
<td>42.40±14.54</td>
<td>3:2</td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
<td>100%</td>
<td>48.13±15.40</td>
<td>1.3:1</td>
</tr>
</tbody>
</table>
Most pathologies were common in older age groups (40-60yrs) except DNET, medulloblastoma, and diffuse midline glioma were present in the younger age group. Almost all pathologies were common in males except meningioma which was twice more common in female than male.
Table 2: Conventional MR features in different pathologies

<table>
<thead>
<tr>
<th>Pathology</th>
<th>Calcification</th>
<th>Haemorrhage</th>
<th>Margins</th>
<th>Cystic/Necrotic Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Well Defined</td>
<td>Ill Defined</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>8(18%)</td>
<td>16(37%)</td>
<td>24(54%)</td>
<td>20(46%)</td>
</tr>
<tr>
<td>High Grade Glioma</td>
<td>1(10%)</td>
<td>8(80%)</td>
<td>1(10%)</td>
<td>6(100%)</td>
</tr>
<tr>
<td>Glioblastoma Multiforme</td>
<td>1(17%)</td>
<td>6(100%)</td>
<td>3(100%)</td>
<td>3(100%)</td>
</tr>
<tr>
<td>Grade III Astrocytoma</td>
<td>2(67%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse Midline Glioma</td>
<td></td>
<td></td>
<td>1(100%)</td>
<td></td>
</tr>
<tr>
<td>Low Grade Glioma</td>
<td>1(20%)</td>
<td>1(20%)</td>
<td>4(80%)</td>
<td>1(20%)</td>
</tr>
<tr>
<td>Grade II Astrocytoma</td>
<td></td>
<td></td>
<td>4(100%)</td>
<td></td>
</tr>
<tr>
<td>Grade II Oligodendroglioma</td>
<td>1(100%)</td>
<td>1(100%)</td>
<td>1(100%)</td>
<td></td>
</tr>
<tr>
<td>Meningioma</td>
<td>6(67%)</td>
<td>3(33%)</td>
<td>6(67%)</td>
<td>3(33%)</td>
</tr>
<tr>
<td>Atypical Meningioma</td>
<td>2(100%)</td>
<td>2(100%)</td>
<td>2(100%)</td>
<td></td>
</tr>
<tr>
<td>Benign Meningioma</td>
<td>4(57%)</td>
<td>1(14%)</td>
<td>6(85%)</td>
<td>1(14%)</td>
</tr>
<tr>
<td>DNET</td>
<td></td>
<td></td>
<td>4(100%)</td>
<td></td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td></td>
<td></td>
<td>1(100%)</td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td>4(27%)</td>
<td>4(27%)</td>
<td>11(73%)</td>
<td></td>
</tr>
<tr>
<td>Non-Neoplastic</td>
<td>3(19%)</td>
<td>1(6%)</td>
<td>16(100%)</td>
<td></td>
</tr>
<tr>
<td>Abscess</td>
<td></td>
<td></td>
<td>6(100%)</td>
<td></td>
</tr>
<tr>
<td>Neurocysticercosis</td>
<td>3(60%)</td>
<td></td>
<td>5(100%)</td>
<td></td>
</tr>
<tr>
<td>Tuberculoma</td>
<td></td>
<td>1(20%)</td>
<td>5(100%)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>11(18%)</td>
<td>17(28%)</td>
<td>36(60%)</td>
<td>24(40%)</td>
</tr>
</tbody>
</table>

Calcification in neoplastic group was common in 6(67%) cases of meningioma, 1 case(16.67%) of glioblastoma multiforme and 1 case(100%) of grade II oligodendroglioma. No calcification was present in cases of grade II diffuse astrocytoma. In non-neoplastic pathologies calcification was seen in 60% cases of neurocysticercosis. Haemorrhage, marked perilesional oedema, ill-defined margins, cystic/necrotic changes were more common in HGG than the LGG. Haemorrhage was present in all cases of glioblastoma multiforme, 2 case (67%) of grade III anaplastic astrocytoma and 1 case (100%) of grade II oligodendroglioma. No haemorrhage was present in any case of grade II diffuse astrocytoma. Cyst/necrotic changes were present in all cases of HGG. None of LGG showed cystic or necrotic changes in any of cases. In non-neoplastic pathologies all lesions had well defined margins and 1(20%) of cases tuberculoma had hemorrhagic foci.

Table 3: Distribution of nADC value in lesion and perilesional oedema in DWI and rCBV in PWI among different pathology
<table>
<thead>
<tr>
<th>Pathology</th>
<th>ADC Value in Lesion</th>
<th>ADC Value in Perilesional Oedema</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade II Astrocytoma</td>
<td>1.42±0.06</td>
<td>1.88±0.10</td>
</tr>
<tr>
<td>Grade II Oligodendroglioma</td>
<td>1.36</td>
<td>1.82</td>
</tr>
<tr>
<td>Meningioma</td>
<td>1.08±0.12</td>
<td>1.80±0.09</td>
</tr>
<tr>
<td>Atypical Meningioma</td>
<td>0.91±0.10</td>
<td>1.84±0.12</td>
</tr>
<tr>
<td>Benign Meningioma</td>
<td>1.12±0.08</td>
<td>1.79±0.09</td>
</tr>
<tr>
<td>DNET</td>
<td>2.54±0.12</td>
<td>1.81±0.09</td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>0.99</td>
<td>1.46</td>
</tr>
<tr>
<td>Metastasis</td>
<td>1.16±0.11</td>
<td>1.82±0.08</td>
</tr>
<tr>
<td>Non-Neoplastic</td>
<td>0.71±0.09</td>
<td>1.81±0.10</td>
</tr>
<tr>
<td>Abscess</td>
<td>0.65±0.05</td>
<td>1.85±0.10</td>
</tr>
<tr>
<td>NCC</td>
<td>0.80±0.10</td>
<td>1.76±0.09</td>
</tr>
<tr>
<td>Tuberculoma</td>
<td>0.69±0.06</td>
<td>1.81±0.09</td>
</tr>
</tbody>
</table>

**Chart 3:** Distribution of nADC value in the lesion and perilesional oedema among different pathology

**Chart 4:** Showing rCBV values in different pathologies
In neoplastic pathologies LGG, ADC values were higher than the HGG, suggesting no restriction of diffusion and ADC values in perilesional oedema were not significantly lower. ADC values were lower in HGG and metastatic lesions. However, the ADC values in perilesional oedema were lower in HGG than the metastatic lesions, suggesting infiltrative process in HGG. One case of oligodendroglioma and medulloblastoma shows decreased ADC values. DNET shows significantly higher ADC values within the lesion, suggesting increased diffusivity. Atypical menigioma shows lower ADC values than the benign menigioma and ADC values in perilesional oedema were not significantly lower in both grades of menigiomas. Non-neoplastic pathologies show lower ADC values suggesting restricted diffusion. Abscess and tuberculoma both show lower ADC values. However perilesional ADC values were not decreased.

On PWI, rCBV values were lower in LGG than the HGG and metastatic lesions. However, discrimination between metastases and HGG was not possible with rCBV values alone. Each of one case of oligodendroglioma and medulloblastoma showed lower rCBV values. Meningiomas showed highly increased rCBV values suggesting hyper vascular tumor. Atypical menigioma shows higher rCBV values than the benign menigioma. DNET show significantly lower rCBV values within the lesion, suggesting absent perfusion. Abscess showed significantly lower rCBV values in the wall, while walls of tuberculomas showed higher rCBV values.

Table 4: Distribution of MR spectroscopy spectrum values in different pathologies

<table>
<thead>
<tr>
<th>Pathology</th>
<th>NAA/Cr (Mean±SD)</th>
<th>Cho/NAA (Mean±SD)</th>
<th>Cho/Cr (Mean±SD)</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoplastic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Grade Glioma</td>
<td>1.22±0.69</td>
<td>3.01±1.86</td>
<td>2.86±1.41</td>
<td></td>
</tr>
<tr>
<td>GBM</td>
<td>0.33±0.11</td>
<td>5.75±1.15</td>
<td>2.25±0.36</td>
<td>Lac, Lip</td>
</tr>
<tr>
<td>Grade III Astrocytoma</td>
<td>0.38±0.11</td>
<td>5.34±1.03</td>
<td>2.21±0.27</td>
<td></td>
</tr>
<tr>
<td>Diffuse Midline Glioma</td>
<td>0.24±0.05</td>
<td>6.91±0.59</td>
<td>2.45±0.52</td>
<td></td>
</tr>
<tr>
<td>Low Grade Glioma</td>
<td>0.34±0.08</td>
<td>4.79</td>
<td>1.94</td>
<td>Lac</td>
</tr>
<tr>
<td>Grade II Astrocytoma</td>
<td>0.56±0.08</td>
<td>3.43±0.55</td>
<td>1.60±0.16</td>
<td></td>
</tr>
<tr>
<td>Grade II Oligodendroglioma</td>
<td>0.51</td>
<td>3.82</td>
<td>1.83</td>
<td></td>
</tr>
<tr>
<td>Meningioma</td>
<td>1.47±0.32</td>
<td>2.55±1.4</td>
<td>3.41±1.29</td>
<td>Ala</td>
</tr>
<tr>
<td>Atypical Meningioma</td>
<td>1.12±0.16</td>
<td>4.63±0.60</td>
<td>5.16±1.23</td>
<td>Ala, Lac</td>
</tr>
<tr>
<td>Benign Meningioma</td>
<td>1.58±0.27</td>
<td>1.96±0.85</td>
<td>2.91±0.81</td>
<td>Ala</td>
</tr>
<tr>
<td>DNET</td>
<td>1.49±0.19</td>
<td>0.78±0.05</td>
<td>1.16±0.22</td>
<td></td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>0.97</td>
<td>8.12</td>
<td>7.56</td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td>1.83±0.46</td>
<td>1.99±0.65</td>
<td>3.50±1.10</td>
<td>Lac, Lipid</td>
</tr>
<tr>
<td>Non-Neoplastic</td>
<td>0.97±0.47</td>
<td>2.43±1.10</td>
<td>1.97±0.83</td>
<td></td>
</tr>
<tr>
<td>Abscess</td>
<td>1.47±0.40</td>
<td>2.53±1.00</td>
<td>2.73±0.43</td>
<td>Lac, AA, Suc</td>
</tr>
<tr>
<td>NCC</td>
<td>0.74±0.06</td>
<td>1.23±0.06</td>
<td>0.90±0.05</td>
<td>Lac, AA, Suc, Ala</td>
</tr>
<tr>
<td>Tuberculoma</td>
<td>0.59±0.05</td>
<td>3.50±0.09</td>
<td>2.14±0.12</td>
<td>Lac, AA, SucLipid</td>
</tr>
</tbody>
</table>
On spectroscopy, non-neoplastic lesions such as brain abscesses are marked by decreases in Cho, Cr, and NAA, while tumors generally have elevated Cho and decreased levels of Cr and NAA. In HGG, choline peaks and Lactate peaks were higher than the LGG. A few tumors, including glioblastoma multiforme and metastases, showed lipid signal combined with lactate signal. Meningioma showed prominent choline, decreased NAA, Creatine, and presence of alanine. Higher grade meningiomas showed lactate peak. One case of medulloblastoma showed highly increased choline. DNETs showed nearly normal MRS spectrum. In abscesses, there were various combinations of lactate, acetate, succinate, and amino acids. In cysticercosis, resonances of lactate, succinate, alanine, acetate were present. Tuberculomas had a high peak of lipids, more choline, and less NAA and creatine. The choline/creatine ratio was higher than 1 in all tuberculomas compared to none of the cysticerci.

Case 1: Glioblastoma Multiforme

A case of glioblastoma multiforme in a 65-year-old-female. (A) hypointense lesion on T1WI and (B) hyperintense on T2WI in the right parietooccipital region.
Sagittal T1+C (C) images show multiple rings enhancing lesions. SWI (D) show blooming due to haemorrhagic foci.

On MRS (E) demonstrates elevated Cho and decreased NAA, as well as increased lactate (marked with yellow arrow), these findings are further illustrated with spectroscopic colour map (F) of the cho/cr ratios.

Case 2: Diffuse Midline Glioma
A case of diffuse midline glioma in a 12-year-old-child. (A) Axial and (B) Sagittal TIWI shows hypointense and (C) Axial T2WI and (D)Coronal FLAIR images show hyperintense lesion involving pons and midbrain with mass effect.

(G) DWI and (H) ADC images show mild diffusion restriction, however foci of increased diffusion are present (necrotic area, marked with yellow arrow).

(I) Axial T1+C and (J) PWI show enhancement in peripheral part of lesion and (J) PWI show no significant perfusion on the corresponding parametric maps (marked with yellow arrow).
On MRS (K) demonstrates markedly elevated Cho and decreased NAA, as well as increased lactate (marked with yellow arrow), these findings are further illustrated with spectroscopic colour map (L) of the choline/creatine ratios.

Case 3: Metastasis

(A) Axial T1WI
A case of intracranial lung metastasis in a 70-year-old-man. (A) Axial and (B) sagittal T1WI at different levels shows multiple hypointense (two lesions were hyperintense due to haemorrhage) involving bilateral cerebral hemisphere, mid brain and cerebellum.

(C) Axial T2WI

(D) Axial FLAIR

(C) Axial T2WI and (D) Axial FLAIR images at different section, shows hyperintense lesion on T2WI and hyper/isointense lesions with surrounding oedema.
On T1+C(E) images lesions show rim enhancement. On (F)DWI and (G)ADC no restriction was present in centre of lesions (corresponding to necrosis), however mild restriction was present in wall of the lesion.

SWI(H) and phase images(I) show blooming in one lesion due to haemorrhage.
PWI (J) rCBV colour map shows markedly increased perfusion at the margin of the lesion (blue arrow); MR spectrum (K) of the lesion shows elevation of the lactate (Lac) and lipid peak (at 1.33 ppm) (yellow arrow) at short TE.

**Case 4: Atypical Meningioma**
A case of atypical meningioma in a 45-year-old-female. Axial (A)T1W, Sagittal (B)T1W, Axial(C)T2WI and Axial(D)FLAIR images show heterogenous isointense left parietal lobe lesion with surrounding oedema.

T1+C(E)show heterogenous enhancement with peritumoral cyst and PWI(F)show markedly increased perfusion.
DWI(G) and ADC(H) show no restriction with necrotic foci.

SWI (I) and Phase images (J) show calcific foci, MR spectrum (K) of the lesion shows increased Cho and decreased NAA, elevation of the alanine (yellow arrow).

Case 5: Abscess
A case of cerebral abscess in a 48-year-old-male. (A) T1WI hypointense and (C) T2WI/(D) FLAIR hyperintense centre surrounded by an iso-intense wall showing ring enhancement on (B) T1W+C images in the right parietotemporal region.

DWI (E) & ADC (F) show restricted diffusion in the centre of the lesion.

SWI (G) shows dual ring sign; (H) rCBV colour map shows markedly reduced perfusion within the lesion (yellow arrow), MRS (I) of the lesion shows decreased choline and increased lipid and lactate.
Discussion

In comparison to our results, Tilgner J et al (2005)1 in one of the largest stereotactic brain biopsy series of 5000 patients reported that most common intraaxial brain masses were high-grade primary neoplasms (36%), low-grade primary neoplasms (33%), metastases (8%), lymphoma (5%), demyelinating and inflammatory conditions (3%), infarcts (2%), and abscesses (1%). Some discrepancies in results were there may be due to the smaller sample size of our study and a smaller number of infective pathologies in developed countries. The similar finding also reported by Nicollas Nunes Rabelo et al (2016)2 and Baghdady A et al (2016)3 in their respective studies.

Most common pathology in the neoplastic group was metastases (34% of neoplastic lesions) followed by HGG (22.22%), meningiomas (21%). The mean age of neoplastic lesions was 50.27±15.82 years and was more common in the male population with a M:F ratio of 1.37:1. Similar results obtained by Tilgner J et al (2005)1 and Shan F Y et al (2017)4 in their respective studies. Most common pathology in the non-neoplastic group were abscess 6 cases (38%) followed by tuberculoma and neurocysticercosis, each comprises 31.5% of non-neoplastic lesions. The mean age of non-neoplastic lesions was 42.25±12.86 years and was more common in the male population. Similar results obtained in studies by Hourani R, et al (2008)5 and Nicollas Nunes Rabelo et al (2016)2 in their respective studies.

In our study, on DWI, neoplastic lesions had higher ADC values (1.27±0.43) than the non-neoplastic lesions (0.71±0.09). However, both groups of lesions showed decreased ADC in comparison to normal brain parenchyma. On PWI, neoplastic lesions had higher rCBV (5.12±3.19) than the non-neoplastic lesions (1.69±1.11). On MRS, NAA/Cr, Cho/NAA and Cho/Cr ratios in neoplastic lesions were 1.22±0.69, 3.01±1.86 and 2.86±1.41 respectively. While in non-neoplastic lesions NAA/Cr, Cho/NAA and Cho/Cr ratios were 0.97±0.47, 2.43±1.10 and 1.97±0.83 respectively. Our study findings were comparable to studies done by Yamasaki et al (2005)6, Hourani R, et al (2008)5 and Moller-Hartmann W (2002)7.

Glioma

In our study, on DWI low grade glioma has higher nADC values than the HGG. nADC values in the lesions were 1.07±0.43 and 1.41±0.06 in HGG and LGG respectively. Significantly, lower nADC values in perilesional oedema were present in the HGG in comparison to LGG and metastases suggesting tumour infiltration in HGG. On PWI for HGG and LGG rCBV values were 4.54±1.41 and 1.33±0.27, respectively. The mean rCBV ratio for glioblastomas and Grade II Astrocytoma were 5.36±0.68 and 1.37±0.30, respectively. On MRS, gliomas showed increased choline signals, decreased intensities of creatine and NAA compared to normal parenchyma. NAA/Cr, Cho/NAA and Cho/Cr ratios were 0.33±0.11, 5.75±1.15 and 2.25±0.36 in HGG and 0.56±0.08, 3.43±0.55 and 1.60±0.16 in LGG respectively. HGG showed increase in lactate and in few glioblastoma lipid peaks were also present. Our study finding correlated with studies of Lu et al (2004)8, Mehrabian et al (2019)9, Hakyemez B et al (2006)10, Lai et al (2002)11 and Wang et al (2017)12.

Metastases

In our study, on DWI, nADC values in the metastatic lesions and perilesional oedema were 1.16±0.11 and 1.82±0.08. nADC values were decreased comparable to HGG but perilesional nADC values were not decreased as the HGG. On PWI the mean rCBV ratio for metastatic lesions was 5.19±1.30. On MRS, NAA/Cr, Cho/NAA and Cho/Cr ratios in metastatic lesions were 1.83±0.46, 1.99±0.65 and 1.97±0.83 respectively and lipid/lactate peak were present in 12 cases (80%). Similar to studies done by Hakyemez B et al (2006)10, Chatterjee S et al (2009)13 and Poptani H (1995)14.
**Meningiomas**  
On DWI, nADC values in atypical and typical meningioma were 0.913±0.06 and 1.125±0.08 respectively. On PWI meningiomas were hypervascular and the mean rCBV ratio for typical and atypical meningiomas were 9.5 and 11.5 respectively. On MRS mean values of NAA/Cr, Cho/Cr and Cho/NAA for typical meningiomas were 1.58±0.27, 1.96±0.85 and 2.91±0.81 respectively and for atypical meningiomas were 1.12±0.16, 4.63±0.60 and 5.16±1.23 respectively. Our study well correlated with studies done by Nagar et al(2009)\(^{15}\), Hakyemez B et al(2006)\(^{10}\), Lin MC et al(2018)\(^{16}\) and Cho Y D et al(2003)\(^{17}\).

**DNET**  
On PWI, DNET shows lower cerebral blood values than normal parenchyma with mean rCBV= 0.88. On MRS, no significant differences were detected in Cho/NAA, NAA/ Cr or Cho/Cr ratios between DNET and normal brain. On DWI, lesions had higher ADC values (2.54±0.12). Bulakbasi N et al(2007)\(^{18}\) also reported no significant differences were detected on spectroscopy between DNET and normal brain, higher ADC values and lower cerebral blood values than normal parenchyma.

**Abscess**  
On DW imaging, central restriction were present in all cases with mean nADC values in abscess were 0.65±0.05. On PWI, mean rCBV ratio in the wall were 0.77±0.06 and on MRS mean values of NAA/Cr, Cho/Cr and Cho/NAA for abscess were 1.47, 2.53 and 2.73 respectively with amino acid, succinate, and lactate peaks. Lipid peak was not present in any case. Our study well correlated with studies of Lai PH et al(2002)\(^{11}\), Chiang IC et al(2009)\(^{19}\) and Toh C et al(2014)\(^{20}\).

**Tuberculoma**  
On DW imaging, variable degree of restriction were present in all cases with mean nADC values in tuberculoma were1.33±0.51. On PWI, mean rCBV ratio in the wall were 3.20±0.51. On MRS mean values of NAA/Cr, Cho/Cr and Cho/ NAA for tuberculoma were 0.59, 3.50 and 2.14 respectively. Tuberculomas had a high peak of lipids, more choline, less NAA and creatine. Our study well correlated with studies done by Vasudev S et al(2007)\(^{21}\), Batra & Tripathi et al(2004)\(^{22}\), Ghosh RN et al(2018)\(^{23}\) and Pretell E J et al(2005)\(^{24}\).

**Neurocysticercoses**  
On DWI, variable degree of restriction was present in all cases with mean nADC values were 0.80±0.10. On PWI, mean rCBV ratio in the wall were 1.27±1.2. On MRS mean values of NAA/Cr, Cho/Cr and Cho/ NAA were 0.74, 1.23 and 0.90 respectively. In two cases alanine (Peaks at 1.5 and 1.6), succinate(peak at 2.4 ppm) in 3 cases, lactate peak in all cases were present. Our study well correlated with the studies done by Santos GT et al(2013)\(^{25}\), Ghosh RN et al(2018)\(^{23}\) and Pretell E J et al(2005)\(^{24}\).

**Conclusion**  
Although conventional MRI is, undoubtedly, the most sensitive modality available for the detection of brain tumours, it has low specificity. Intracranial masses may be life-threatening lesions that are refractory to even the most aggressive therapy or benign and require only occasional observation.

In practice, a tumour (e.g. glioma) is a lesion that should be treated aggressively, whereas a non-neoplastic lesion can be treated more conservatively. Misinterpretation may lead to a significant delay of adequate treatment of malignant tumours or may result in over-treatment of a tumour-like, benign lesion. Greater accuracy in imaging evaluation is important to plan appropriate management, especially when they occur at sites of high risk for biopsy.

In this regard, it should also be noted that biopsy only provides information about a portion of the neoplasm and not necessarily about the whole of it. A more accurate non-invasive approach implies extending the attainable information beyond the mere morphological parameters of contrast enhancement and vasogenic oedema observed on conventional imaging.
The recent development of functional MRI sequences such as diffusion tensor imaging, perfusion-weighted imaging, magnetic resonance spectroscopy and susceptibility-weighted imaging facilitates the differentiation between tumour and tumour-like lesions. Integration of diagnostic information from above mentioned advanced MR imaging techniques not only can differentiate between neoplastic and non-neoplastic lesions with higher sensitivity and specificity but also help in evaluate different tumour types, predict tumour grade, improve the classification accuracy, serially and noninvasively monitor tumour progression, monitor the efficacy of therapy. So, these advanced imaging methods should be used routinely as a valuable non-invasive tool besides conventional MRI, whenever available, to reach a definitive final diagnosis in cases of brain tumours and tumour like lesions.

Bibliography


